All In MedTech

Company

Organon

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements.

Public

Listed

OGN

NYSE · Organon & Co.

Public float

$2.50B

Value of shares held by non-insiders on Jun 30, 2025

Revenue

$6.22B

Fiscal year ending Dec 31, 2025

Net income

$187M

Fiscal year ending Dec 31, 2025

R&D spending

$366M

Fiscal year ending Dec 31, 2025

Cash

$1.46B

As of Sep 30, 2026

Long-term debt

$8.55B

As of Sep 30, 2026

Shares outstanding

262.6M

As of Oct 23, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2025––$1.05B–
2024––$1.19B–
2023––$80.0M–
2021––$9.47B–

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

The investor database is free with an account

For Organon we have 4 shareholders with 5% or more.

Sign up free with your name, company and ZIP code to see the 5%+ shareholders and government grant funders behind device companies.

Latest FDA decisions

Search the Clearance Tracker

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar

3 more trials with a free account

Reports received

7

Received Nov 1, 2025 to Nov 20, 2026

Malfunction reports

2

29% of reports

Injury reports

3

43% of reports

Death reports

2

29% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 230200
Jan 240200
Feb 2421100
Mar 241900
Apr 2411200
May 240700
Jun 240100
Jul 2401500
Aug 242810
Sep 240700
Oct 240510
Nov 240400
Dec 241020
Jan 250400
Feb 251100
Mar 2514100
Apr 251500
May 250300
Jun 250100
Jul 250400
Aug 250300
Sep 251220
Oct 250300
Nov 250000
Dec 251000
Jan 260100
Feb 260010
Mar 260110
Apr 260000
May 261100
Jun 260000
Jul 260000
Aug 260000
Sep 260000
Oct 260000
Nov 260000

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.